Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
02 juin 2023 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2023 it granted stock options to purchase an aggregate of...
Cytokinetics to Participate in Upcoming Investor Conferences
01 juin 2023 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor...
Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress
20 mai 2023 10h30 HE
|
Cytokinetics, Incorporated
Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical...
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress
15 mai 2023 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one Late Breaking Clinical Trial presentation and two moderated ePoster...
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586
11 mai 2023 07h30 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized,...
Cytokinetics to Participate in the JMP Securities Life Sciences Conference
08 mai 2023 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
Cytokinetics Reports First Quarter 2023 Financial Results
04 mai 2023 16h00 HE
|
Cytokinetics, Incorporated
SEQUOIA-HCM Nearing Completion of Enrollment; On Track for Results in Q4 2023 Additional Data from Cohort 4 of REDWOOD-HCM to be Presented in Late-Breaking Clinical Trial Session at European Society...
Cytokinetics to Hold Annual Meeting of Stockholders
03 mai 2023 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 10,...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 mai 2023 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 28, 2023 it granted stock options to purchase an aggregate of...
Cytokinetics to Announce First Quarter Results on May 4, 2023
20 avr. 2023 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2023 at 4:00...